Global Epilepsy Drugs Market 2016-2020

Global Epilepsy Drugs Market 2016-2020

Category : Pharmaceuticals
Sub Category : Prescription Drugs
Published On : July  2016
Pages : 87



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com
About the Epilepsy Drugs Market
 
Epilepsy is characterized by recurrent seizures caused by the improper balance between inhibitory and excitatory signals in the brain. The symptoms of epilepsy, caused by brain malformations and tumors, birth trauma, and high-risk pregnancies, can be benign or life-threatening. A majority of epilepsy cases have an unknown etiology.  
Etiology 
Etiology varies according to the age of a person. Some individuals genetically inherit the disease while the cause of the disease in others is unknown. Head injuries, tumors, autism spectrum disorder, or stroke can also cause the disorder.  
 
Technavio’s analysts forecast the global epilepsy drugs market to grow at a CAGR of 4.45% during the period 2016-2020.
 
Covered in this report 
The report covers the present scenario and the growth prospects of the global epilepsy drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent epilepsy and related seizures. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of marketed drugs during the forecast period.
 
The market is divided into the following segments based on geography: 
• Americas
• APAC
• EMEA
 
Technavio's report, Global Epilepsy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 
 
Key vendors 
• Eisai
• GSK
• Pfizer
• UCB 
 
Other prominent vendors 
• AbbVie
• Acorda Therapeutics
• Alexza Pharmaceuticals
• Aprecia Pharmaceuticals
• Aurobindo Pharma
• Biscayne Pharmaceuticals
• CURx Pharmaceuticals
• Dainippon Sumitomo Pharma
• D-Pharm
• F. Hoffmann-La Roche
• Grupo Ferrer Internacional
• GW Pharmaceuticals
• Insero Health
• INSYS Therapeutics
• Janssen Pharmaceuticals
• Ligand Pharmaceuticals
• H. Lundbeck
• MarcoPolo Pharmaceuticals
• Marinus Pharmaceuticals
• Meda
• Neurelis
• Nobelpharma
• Novartis
• Orphelia Pharma
• SAGE Therapeutics
• SciFlour
• Sedor Pharmaceuticals
• Shire
• SK Biopharmaceuticals
• Sun Pharmaceutical
• Sunovion Pharmaceuticals (US)
• Supernus Pharmaceuticals
• Takeda
• Turing Pharmaceuticals
• Upsher-Smith
• Valeant Pharmaceutical
• Zogenix
 
Market driver 
• Tentative approval of late-stage pipeline molecules
• For a full, detailed list, view our report 
 
Market challenge 
• Social stigma associated with epilepsy
• For a full, detailed list, view our report 
 
Market trend 
• Reformulation of marketed drugs
• For a full, detailed list, view our report 
 
Key questions answered in this report 
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors? 
 
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
• Epilepsy: An overview
PART 05: Pipeline analysis
PART 06: Key buying criteria for anti-epileptic drugs
PART 07: Market landscape
• Market overview
• Five forces analysis
PART 08: Market segmentation by generation of drugs
• First-generation anti-epileptic drugs
• Second-generation anti-epileptic drugs
• Third-generation anti-epileptic drugs
PART 09: Market segmentation by spectrum of activity
• Narrow-spectrum anti-epileptic drugs
• Broad-spectrum anti-epileptic drugs
PART 10: Market segmentation by type of seizures
• Partial onset seizures
• Generalized seizures
PART 11: Geographical segmentation
• Global epilepsy drugs market by geography 2016-2020
• Epilepsy drugs market in Americas
• Epilepsy drugs market in US
• Epilepsy drugs market in EMEA
• Epilepsy drugs market in APAC
• Epilepsy drugs market in Japan
• Epilepsy drugs market in Australia
• Epilepsy drugs market in China
• Epilepsy drugs market in India
PART 12: Market drivers
• Tentative approval of late-stage pipeline molecules
• Special regulatory designations
• Development of novel therapeutics using innovative technologies
PART 13: Impact of drivers
PART 14: Market challenges
• Social stigma associated with epilepsy
• Growing use of seizure management devices is a threat to drug therapies
• Gradual decrease in incentives/investment by vendors for new drug development
PART 15: Impact of drivers and challenges
PART 16: Market trends
• Development of devices and smartphone apps to detect seizures and track medications
• Reformulation of marketed drugs
• Increased uptake of new-generation drugs
PART 17: Vendor landscape
• Competitive scenario
• Key news
PART 18: Key vendor analysis
• Eisai
• GSK
• Pfizer
• UCB
• Other prominent vendors
PART 19: Appendix
• List of abbreviations
PART 20: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Pipeline portfolio: Epilepsy drugs
Exhibit 03: Percentage share of pipeline molecules for global epilepsy drugs market
Exhibit 04: Key buying criteria for anti-epileptic drugs
Exhibit 05: Global epilepsy drugs market snapshot: Developed and emerging markets 2015
Exhibit 06: Global epilepsy drugs market 2015-2020 ($ billions)
Exhibit 07: A few research studies targeting cause of epilepsy
Exhibit 08: Segmentation of marketed anti-epileptic drugs based on mechanism of action
Exhibit 09: Five forces analysis
Exhibit 10: Timeline of development of anti-epileptic drugs
Exhibit 11: Segmentation of global anti-epileptic drugs market based on generation of drugs 2015
Exhibit 12: Opportunity analysis of global epilepsy drugs market by generation of drugs
Exhibit 13: Segmentation of global epilepsy drugs market by the spectrum of activity of drugs 2015
Exhibit 14: Segmentation of global epilepsy drugs market based on type of seizures
Exhibit 15: Global epilepsy drugs market by geography 2015-2020
Exhibit 16: Global epilepsy drugs market by geography 2015 and 2020
Exhibit 17: Global epilepsy drugs market by geography 2015-2020 ($ billions)
Exhibit 18: Epilepsy drugs market in Americas 2015-2020 ($ billions)
Exhibit 19: Epilepsy drugs market in Americas by geography 2015
Exhibit 20: Comparison of US healthcare system: Before and after reforms
Exhibit 21: Epilepsy drugs market in US 2015-2020 ($ billions)
Exhibit 22: Epilepsy drugs market in EMEA by geography 2015
Exhibit 23: Epilepsy drugs market in EMEA 2015-2020 ($ billions)
Exhibit 24: Epilepsy drugs market in APAC 2015-2020 ($ billions)
Exhibit 25: Epilepsy drugs market in APAC by geography 2015
Exhibit 26: Epilepsy drugs market in Japan 2015-2020 ($ millions)
Exhibit 27: Epilepsy drugs market in Australia 2015-2020 ($ millions)
Exhibit 28: Epilepsy drugs market in China 2015-2020 ($ millions)
Exhibit 29: Epilepsy drugs market in India 2015-2020 ($ millions)
Exhibit 30: Impact of drivers
Exhibit 31: Impact of drivers and challenges
Exhibit 32: Position of key vendors in global epilepsy drugs market 2015
Exhibit 33: Geographical presence of key vendors
Exhibit 34: Company portfolio analysis in global epilepsy drugs market 2016-2020
Exhibit 35: Eisai: YoY revenue and growth rate of Fycompa (Americas and EMEA) 2013-2015 ($ millions)
Exhibit 36: Eisai: YoY revenue and growth rate of Zonegran (EMEA) 2013-2015 ($ millions)
Exhibit 37: Eisai: YoY revenue and growth rate of Banzel (Americas and EMEA) 2013-2015 ($ millions)
Exhibit 38: Eisai: YoY revenue and growth rate of Zebinix (EMEA) 2013-2015 ($ millions)
Exhibit 39: Eisai: Metrics analysis
Exhibit 40: GSK: YoY revenue and growth rate of Lamictal 2013-2015 ($ millions)
Exhibit 41: GSK: Metrics analysis
Exhibit 42: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions)
Exhibit 43: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions)
Exhibit 44: Pfizer: Metrics analysis
Exhibit 45: UCB: YoY revenue and growth rate of Keppra 2013-2015 ($ millions)
Exhibit 46: UCB: Geographical segmentation of Keppra by revenue 2015
Exhibit 47: UCB: YoY revenue and growth rate of Vimpat 2013-2015 ($ millions)
Exhibit 48: UCB: Geographical segmentation of Keppra by revenue 2015
Exhibit 49: UCB: Metrics analysis

Enquiry Before Buy
image
Can´t read the image ? refresh here.